Intravesical therapy with adriamycin in patients with superficial bladder tumors.
An 80-mg dose of adriamycin was given intravesically once a month to 58 patients with superficial transitional cell tumor of the bladder. Complete cytological remission was achieved in all 11 patients with previously untreated, flat carcinoma in situ lesions. In 19 carcinoma in situ patients, who were previously treated by other means, cytological remission occurred in 74%. In T1 and T2 papillary tumor remission occurred in 65 and 20%, respectively. Minor local side effects were observed.
D000287:Administration, Topical; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D003558:Cystoscopy; D004317:Doxorubicin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D012075:Remission, Spontaneous; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014546:Urinary Catheterization; D014556:Urine / Q000166:cytology
D004317:Doxorubicin